Evidence map›Paper›PMID 42661642›Full record

ArticleFrontiers in medicine2026

Circulating microRNAs as biomarkers of disease activity and treatment response in Crohn's disease patients receiving infliximab or vedolizumab: a longitudinal cohort study.

Luisa Bertin, Lara Giraldi, Camilla Cavagna, Cristina Caranfil, Brigida Barberio, Romilda Cardin, Sonia Facchin, Chiara Carlotto, Milena Minotto, Edoardo Vincenzo Savarino and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Luisa BertinGastroenterology Unit, Department of Surgery, Oncology and Gastroenterology (DiSCOG), University of Padova, Padova, Italy.
Lara GiraldiGastroenterology Unit, Department of Surgery, Oncology and Gastroenterology (DiSCOG), University of Padova, Padova, Italy.
Camilla CavagnaGastroenterology Unit, Department of Surgery, Oncology and Gastroenterology (DiSCOG), University of Padova, Padova, Italy.
Cristina CaranfilGastroenterology Unit, Department of Surgery, Oncology and Gastroenterology (DiSCOG), University of Padova, Padova, Italy.
Brigida BarberioGastroenterology Unit, Azienda Ospedale-Università di Padova, Padova, Italy.
Romilda CardinGastroenterology Unit, Department of Surgery, Oncology and Gastroenterology (DiSCOG), University of Padova, Padova, Italy.
Sonia FacchinGastroenterology Unit, Department of Surgery, Oncology and Gastroenterology (DiSCOG), University of Padova, Padova, Italy.
Chiara CarlottoGastroenterology Unit, Department of Surgery, Oncology and Gastroenterology (DiSCOG), University of Padova, Padova, Italy.
Milena MinottoGastroenterology Unit, Department of Surgery, Oncology and Gastroenterology (DiSCOG), University of Padova, Padova, Italy.
Edoardo Vincenzo SavarinoGastroenterology Unit, Department of Surgery, Oncology and Gastroenterology (DiSCOG), University of Padova, Padova, Italy.
Fabiana ZingoneGastroenterology Unit, Department of Surgery, Oncology and Gastroenterology (DiSCOG), University of Padova, Padova, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and aims: Validated biomarkers of biologic response in Crohn's disease (CD) are lacking. We assessed whether serum microRNAs (miRNAs) track disease activity and predict outcomes during biologic induction in CD. Methods: Thirty-nine adults with active CD initiating infliximab ( Results: miR-21-5p and miR-146b-5p were significantly reduced in CD versus controls (q < 0.05). Baseline miR-146b-5p inversely predicted post-induction CRP independently of baseline disease severity (partial r = -0.46, Conclusion: Serum miRNAs offer novel predictive (baseline miR-146b-5p and miR-106a-5p) and concurrent (post-induction miR-424-5p) biomarker signals during biologic induction in CD, providing information complementary to faecal calprotectin. Prospective independent validation is warranted before clinical translation.

Indexed as

biomarkerCrohn’s diseasefaecal calprotectininfliximabserum microRNAtreatment responsevedolizumab

Identifiers

PMID42661642
PMCPMC13518191

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.